Angiopoietin–Like 4 Is Involved in the Poor Angiogenic Potential of High Glucose–Insulted Bone Marrow Stem Cells

Yong Sook Kim, PhD,1,2 Hea Jin Kang, BS,1,3 Moon Hwa Hong, BS,1 Wan Seok Kang, MS,1,3 Nakwon Choe, MS,1 Hyun Kook, MD,3,4 Myung Ho Jeong, MD,2,5 and Youngkeun Ahn, MD,1,2,5

1Research Laboratory of Cardiovascular Regeneration, Chonnam National University Hospital, Gwangju, 2Cardiovascular Convergence Research Center, Chonnam National University Hospital, Gwangju, 3Center for Molecular Medicine, Graduate School, Chonnam National University, Gwangju, 4Department of Pharmacology and Medical Research Center for Gene Regulation, Chonnam National University Medical School, Gwangju, 5Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea

Background and Objectives: Diabetes is reported to reduce the function or number of progenitor cells. We compared the gene expression patterns of bone marrow-derived mesenchymal stem cells from diabetic (DM-BMCs) and healthy (non-DM-BMCs) rats and suggested Angiopoietin-like 4 (Angptl4) could be a responsible factor for impaired angiogenesis of DM-BMCs.

Subjects and Methods: BMCs were isolated from DM or non-DM rat, and in vitro angiogenesis activity was compared by tube formation assay on Matrigel and complementary deoxyribonucleic acid expression was analyzed by microarray with or without oxytocin treatment. Human BMCs (hBMCs) were treated with high glucose, and were performed polymerase chain reaction, Western blot, and enzyme-linked immunosorbent assay. Angptl4 plasmid DNA and micro ribonucleic acid-132 (miR-132) were transfected to immortalized hBMCs.

Results: In vitro angiogenesis assay showed the impaired tube formation in DM-BMCs, and slightly recovery by oxytocin treatment. Angptl4, an adipokine, was upregulated in DM-BMCs compared to non-DM-BMCs. Oxytocin treatment reduced Angptl4 in DM-BMCs. In hBMCs, overexpression of Angptl4 attenuated the tube formation. In addition to Angptl4, miR-132 was increased by high glucose treatment. Collectively, high glucose resulted in impaired tube formation through miR-132 induction and Angptl4 upregulation in BMCs.

Conclusion: Our results show that the angiogenic activity of BMCs is impaired by high glucose stress, which would be mediated by Angptl4 and miR-132.

KEY WORDS: Stem cells; Diabetes mellitus; ANGPTL4 protein, rat; MicroRNAs.

Introduction

Bone marrow-derived mesenchymal stem cells (BMCs) are multipotent cells and have been regarded as a promising regenerative cellular therapy in the treatment of ischemic diseases. BMCs are able to differentiate into vascular lineage cells and can be directly incorporated into newly formed vessels.1 Myocardial infarction remains a major cause of morbidity and mortality, and cell therapy has been aroused as a promising option for cardiac repair.

Our previous report showed that stem cells isolated from diabetic rats had a significant decline in cell proliferation and angiogenic activity, and oxytocin treatment restored the angiogenic function.2 Diabetes, obesity, and aging are important stem cell microenvironments and may regulate stem cell function.3-5 In particular, diabetes is a well-known independent risk factor for cardiovascular disease, stroke, peripheral arterial disease, cardiomyopathy, and congestive heart failure,3-8 while diabetes is closely related with poor neovascularization after ischemia.9 Stem cell function to repair and support the injured myocardium declines with age or diabetes, which were representative limitations in the application of an autologous stem cell therapy for aged or diabetic patients with cardiovascular diseases. There is no doubt that diabetes is considerably associated with...
with dysfunction of stem cells, and the responsible factors for diabetes-related dysfunction in stem cells need to be explored.

In this study, we compared the gene expression pattern of BMCs isolated from diabetic rats (DM-BMCs) with that of control cells (non-DM-BMCs), and suggested that Angiopoietin-like 4 (Angptl4) and micro ribonucleic acid-132 (miR-132) could be therapeutic targets for the repair of angiogenic function.

Materials and Methods

Experimental hyperglycemia

The study was approved by the Chonnam National University Institutional Animal Care and Use Committee (Chonnam National University AICUC-H-2010-11). Twelve-week-old adult male Sprague-Dawley rats (Central Lab Animal, Seoul, Korea) received intraperitoneal injections of streptozotocin (65 mg/kg, Sigma-Aldrich, St. Louis, USA) dissolved in 50 mM sodium citrate buffer (pH 4.5) to induce hyperglycemia. Age-matched controls were injected with an equivalent volume of saline. Fasting blood glucose levels were measured in tail veins, and rats with a blood glucose level >250 mg/dL were considered to be diabetic and were included in the study.

Cell cultures

Bone marrow cells were obtained from the tibia and femur under sterile conditions by using a syringe to flush the cavity out with warmed phosphate-buffered saline (PBS), collected by centrifugation, and resuspended with Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum. Cells were plated into culture dishes, and non-adherent cells were removed by changing the medium after 72 hours. All cells used in this study were from the third and fourth passages of BMCs. Oxytocin (100 nM, Sigma-Aldrich, St. Louis, USA) was added to the growth medium for 24 hours for the experiments.

In vitro angiogenesis assay

Tube formation was assayed by using an in vitro angiogenesis assay kit (Chemicon, Billerica, USA). Cells (1 × 10⁴) were plated onto matrix gel-coated 96-well plates and were cultured in DMEM without serum. Tube formation was monitored and photographed by using an inverted microscope (Olympus, Tokyo, Japan), and images were analyzed by using Image-Pro software (MediaCybernetics, Rockville, USA). Angiogenic activity was quantified by measuring tube length and tube area. Total tube length in four fields per well was averaged, and three wells were used to produce one value per condition.

Microarray analysis

To identify the high glucose-responsive genes, we performed complementary deoxyribonucleic acid (cDNA) microarray using DM-BMCs and non-DM-BMCs with or without oxytocin treatment (GenomicTree, Daejeon, Korea). Ribonucleic acid (RNA) quality was assessed using the Agilent 2100 Bioanalyzer, and RNA was amplified by Agilent's Low RNA Input Linear Amplification kit PLUS and hybridized to Agilent Rat expression 4X44K (v3).

Reverse transcriptase-polymerase chain reaction and quantitative real-time polymerase chain reaction

To compare the messenger RNA (mRNA) expression level of Angptl4, cells were homogenized in Trizol (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. cDNA was generated by use of MMLV transcriptase (Invitrogen, Carlsbad, USA). Real-time polymerase chain reaction (PCR) was performed using a QuantiTect SYBR Green PCR kit (Qiagen, Valencia, USA) and Corbett Research Rotor-Gene RG-3000 Real Time PCR System. Primers were purchased (Bioneer, Daejeon, Korea).

Western blot analysis and enzyme-linked immunosorbent assay

Cells were resuspended in lysis buffer (20 mM Tris-HCl, pH 7.4, 0.1 mM ethylenediaminetetraacetic acid, 150 mM NaCl, 1 mM phenylmethanesulfonyl fluoride, 1 mg/mL leupeptin, 1 mM Na3VO4), and kept on ice with occasional tapping for 20 minutes. After centrifugation at 10000×g for 10 minutes, the supernatant was prepared as a protein extract. Equal amount of proteins were fractionated by electrophoreses on 8% or 10% acrylamide gels and were transferred onto a polyvinylidene fluoride (PVDF; Millipore, Billerica, USA) membrane followed by blotting with antibodies against Angptl4 (Sigma-Aldrich, St. Louis, USA), or β-actin (Sigma-Aldrich, St. Louis, USA).

Table 1. Animal characteristics after induction of diabetes with streptozotocin in rats

|                | Non-diabetic group | Diabetic group |
|----------------|--------------------|---------------|
| Day 1 BW (g)   | 415.00±32.84       | 421.82±26.67  |
| Day 1 BG (mg/dL)| 98.10±7.14        | 92.85±4.62    |
| Day 28 BW (g)  | 551.11±25.87      | 318.84±44.79*|
| Day 28 BG (mg/dL)| 114.17±12.77     | 546.03±53.61*|
| Day 28 HW (g)  | 1.36±0.22          | 1.01±0.15*    |
| Day 28 TL (mm) | 44.03±3.82        | 38.24±7.71*   |
| Day 28 HW/TL (mg/mm)| 31.80±1.40      | 27.67±4.45*   |

Data are presented as mean±SD. *p<0.005 vs. non-diabetic. BW: body weight, BG: blood glucose, HW: heart weight, TL: tibia length
The secreted Angptl4 protein in the cell culture media were evaluated by enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, USA).

Plasmid deoxyribonucleic acid and micro ribonucleic acid-132 transfection
Angiopoietin-like 4 plasmid DNA was purchased (Korea Human Gene Bank, Medical Genomics Research Center, KIBB, Daejeon, Korea). BMCS were transfected with plasmid DNA or gWIZ mammalian expression vector (Genlantis, San Diego, USA) by using Lipofectamine 2000 (Invitrogen, Carlsbad, USA) according to the manufacturer’s instruction. Micro ribonucleic acid-132 mimic and control miR, purchased (Bioneer, Daejeon, Korea), were transfected into hBMC using RNAiMAX transfection reagent (Invitrogen, Carlsbad, USA) according to manufacturer’s protocol.

Statistical analysis
All data are presented as means±SDs. P were calculated by using the unpaired Student’s t-test. For analysis of the in vivo ischemia experiments, the Scheffe’s test was performed for multiple comparisons after ANOVA between the groups. A p<0.05 was considered statistically significant.

Results
Tube formation were reduced in DM-BMCs and recovered by oxytocin pretreatment
Hyperglycemia was induced 4 weeks after streptozotocin injection (Table 1), and the mortality was 32% in the diabetic group. Fasting blood glucose was substantially increased at day 28 (114.17±12.77 g/dL in non-diabetic group vs. 546.03±53.61 g/dL in diabetic group).
The body weight was significantly reduced (551.11 ± 25.87 g in non-diabetic group vs. 318.84 ± 44.79 g in diabetic group, \( p < 0.01 \)) and the heart weight/tibia length ratio was significantly reduced in diabetic group (31.80 ± 1.40 in non-diabetic group vs. 27.67 ± 4.45 in diabetic group, \( p < 0.01 \) ) (Table 1).

As shown in Fig. 1, few tubes were formed in DM-BMCs on Matrigel compared to in non-DM-BMCs. After pretreatment with 100 nM of oxytocin for 24 hours, tube formation was partially restored in oxytocin-treated DM-BMCs than in PBS-treated DM-BMCs (Fig. 1B).

Angiopoietin-like 4, one of the diabetes-related genes, were involved in high glucose-insulted tube formation in BMCs. In a cDNA array, several genes were altered in their expression levels in DM-BMCs. Among them, we selected 9 genes which were upregulated in DM-BMCs. Listed are the gene names and expression ratios for each individual array for cDNA microarray. DM/Non DM: the array ratio of DM to Non DM, OT-DM/DM: the array ratio of oxytocin-treated DM to none-treated DM, DM: bone marrow stem cells isolated from diabetic rat, OT: oxytocin, Non DM: bone marrow stem cells isolated from non-diabetic rat, Angptl4: angiopoietin-like 4, Tgfb1: tumor growth factor-\( \beta \), Col14\( \alpha \)1: collagen, type 14, \( \alpha \)1, Procr: endothelial protein C receptor, Esm1: endothelial cell-specific molecule 1, Ednra: endothelin receptor Type A, Bmpr: bone morphogenetic protein-binding endothelial regulator, Myod1: myogenic differentiation 1, Pcdhb5: Protocadherin \( \beta \)5, Sfrp4: secreted frizzled-related protein 4.

### Table 2. Diabetes-induced alterations in gene expression

| Gene        | DM#1/DM#2  | OT-DM#1/DM#2 |
|-------------|------------|--------------|
| Angptl4     | ↑ 9.13     | 0.64         |
| Tgfb1       | ↓ 0.47     | 1.22         |
| Col14\( \alpha \)1 | ↑ 9.12 | 0.82         |
| Procr       | ↓ 0.93     | 1.44         |
| Esm1        | ↓ 0.07     | 1.39         |
| Ednra       | ↓ 0.97     | 0.67         |
| Bmpr        | ↓ 0.57     | 1.30         |
| Myod1       | ↓ 0.02     | 1.58         |
| Pcdhb5      | ↓ 0.60     | 5.07         |
| Sfrp4       | ↓ 0.54     | 1.68         |

Fig. 2. Responsible genes for angiogenic dysfunction of DM-BMCs. A: seven genes were selected as diabetes-responsible genes. Their mRNA expression patterns were characterized with a reference line. Angptl4 and col14\( \alpha \)1 were upregulated in DM-BMCs. Error bars indicate standard deviation. B: mRNA expression levels of Angptl4 in non-DM-BMCs or DM-BMCs with or without oxytocin treatment. DM-BMC: bone marrow-derived mesenchymal stem cells from diabetic rats, mRNA: messenger ribonucleic acid, Angptl4: angiopoietin-like 4, col14\( \alpha \)1: collagen, type 14, \( \alpha \)1, Tgfb1: tumor growth factor-\( \beta \), Procr: endothelial protein C receptor, Esm1: endothelial cell-specific molecule 1, Ednra: endothelin receptor Type A, Bmpr: bone morphogenetic protein-binding endothelial regulator.

Fig. 3. Impaired tube formation of the immortalized hBMCs by high glucose treatment. A: in vitro angiogenesis assay showed the retarded tube formation after high glucose treatment in hBMCs. B: angptl4 mRNA was increased by high glucose treatment, and this increased Angptl4 was reduced by oxytocin treatment. Angptl4: angiopoietin-like 4, OT: oxytocin, hBMCs: human BMCs, mRNA: messenger ribonucleic acid, HG: high glucose.

27.67 ± 4.45 in diabetic group, \( p < 0.01 \) (Table 1).

As shown in Fig. 1, few tubes were formed in DM-BMCs on Matrigel compared to in non-DM-BMCs. After pretreatment with 100 nM of oxytocin for 24 hours, tube formation was partially restored in oxytocin-treated DM-BMCs than in PBS-treated DM-BMCs (Fig. 1B).

Angiopoietin-like 4, one of the diabetes-related genes, were involved in high glucose-insulted tube formation in BMCs. In a cDNA array, several genes were altered in their expression levels in DM-BMCs. Among them, we selected 9 genes which were...
rebounded to basal level in part (Table 2). After repeated reverse transcriptase-polymerase chain reaction, the expression patterns of 7 genes were analyzed and expressed as a graph. By the standard of reference line, Angptl4 and collagen, type 14, α1 (Col14α1) were upregulated, while tumor growth factor-β1 (Tgfb1), endothelial protein C receptor (Procr), endothelial cell-specific molecule 1 (Esm1), endothelin receptor type A (Ednra), and bone morphogenetic protein-binding endothelial regulator (Bmper) were downregulated (Fig. 2A).

The upregulated mRNA of Angptl4 was reduced in oxytocin-treated DM-BMCs (Fig. 2B).

High glucose insulted the human bone marrow-stem cells via angiopoietin-like 4 upregulation

To perform the mechanistic study, the immortalized hBMCs were utilized. The tube formation was reduced in hBMCs with high glucose (25 mM) treatment (Fig. 3A). Angptl4 mRNA level was increased in high glucose-treated hBMCs for 9 days, and reduced in part by oxytocin treatment in high-glucose treated hBMCs (Fig. 3B).

To examine the involvement of Angptl4 in hBMCs tube formation, Angptl4 was overexpressed in hBMCs. After two days of transfection of mock vector or Angptl4 plasmid to hBMC, tube formation was assessed. No tubes were formed in Angptl4-transfected cells. B: induction of Angptl4 mRNA was measured by real-time PCR. C: the released Angptl4 protein was quantified by ELISA. Error bars indicate SD. *p<0.05 vs. mock-transfected DM-BMCs. Angptl4: angiopoietin-like 4, DM-BMC: bone marrow-derived mesenchymal stem cells from diabetic rats, hBMC: human BMC, mRNA: messenger ribonucleic acid, PCR: polymerase chain reaction, ELISA: enzyme linked immuno sorbent assay.

Fig. 4. Overexpression of Angptl4 into hBMCs impaired angiogenic activity. A: after transfection of mock vector or Angptl4 plasmid to hBMC, tube formation was assessed. No tubes were formed in Angptl4-transfected cells. B: induction of Angptl4 mRNA was measured by real-time PCR. C: the released Angptl4 protein was quantified by ELISA. Error bars indicate SD. *p<0.05 vs. mock-transfected DM-BMCs. Angptl4: angiopoietin-like 4, DM-BMC: bone marrow-derived mesenchymal stem cells from diabetic rats, hBMC: human BMC, mRNA: messenger ribonucleic acid, PCR: polymerase chain reaction, ELISA: enzyme linked immuno sorbent assay.

Fig. 5. Involvement of miR-132 and Angptl4 in high-glucose treated Tert-hBMCs. A: endogenous miR-132 was measured by real-time PCR over times in hBMCs and was upregulated by high-glucose treatment in hBMCs. Error bars indicate standard deviation. B: miR-132 transfected hBMCs showed the impaired tube formation. C: angptl4 protein was increased in miR-132-overexpressed hBMCs comparison to mock-transfected cells. D: the level of endogenous miR-132 was not changed by Angptl4 transfection in hBMCs. N: normal glucose, H: high glucose, miR-132: micro ribonucleic acid-132, Angptl4: angiopoietin-like 4, hBMC: human BMC.
Micro ribonucleic acid-132 was involved in impaired tube formation via angiopoietin-like 4 upregulation

Endogenous miR-132 level was examined in hBMC with high glucose treatment over time. In comparison with normal glucose treated hBMCs, high glucose treated hBMCs increased miR-132 level. The level of miR-132 peaked at day 4, and returned to basal level (Fig. 5A). To examine whether miR-132 was directly related with angiogenic activity in hBMCs, miR-132 was transfected for 2 days. miR-132 transfected hBMCs showed poor tube formation compared to miR control transfected hBMCs (Fig. 5B), and showed increased protein level of Angptl4 (Fig. 4C). Next, miR-132 level was measured after transfection with Angptl4 into hBMCs to determine if Angptl4 was the upregulator of miR-132. Angptl4-overexpressed hBMCs showed no tube formation. Additional interest was that Angptl4 was increased by miR-132 transfection in hBMCs (Fig. 4B, C).

Discussion

Cell therapy with autologous BMCs is clinically feasible without ethical issues or immunological problems. Senescence or systemic conditions affect the application of autologous BMCs, and may contribute to the functional decline of stem cells. Several studies reported that diabetes impairs the neovascularization of BMCs.

In previous studies, we provided the evidence for beneficial roles of oxytocin in recovering the angiogenic potential via Kruppe-like factor-2 in DM-BMCs. To understand the mechanism that regulates stem cell function in the high glucose stress, we next explored which factor was contributing in disturbing the angiogenic potential. In microarray analysis, there were a number of genes which were altered in DM-BMCs and restored by oxytocin treatment. Our candidate genes were Angptl4, Tgfβ1, Col14α1, Procr, Esm1, Ednra, Bmpr, myogenic differentiation 1 (Myod1), protocadherin β5 (Pcdhβ5), and secreted frizzled-related protein 4 (Sfrp4) (Table 2). Among them, we selected Angptl4 as a putative responsible gene.

Angiopoietin-like-4 is a secreted adipokine and involved in lipoprotein metabolism. Angptl4 modulate the vascular integrity in tissue-specific manner, and the role of Angptl4 in angiogenesis and vascular permeability remains controversial.

In DM-BMCs, Angptl4 was dramatically increased compared with non-DM-BMCs (Fig. 2). In other words, DM-BMCs were exposed to diabetic niches for 4 weeks, and it was suggested that Angptl4 might be induced by high glucose stress. To confirm the relationship of Angptl4 with high glucose stress, hBMCs were treated with 25 mM glucose. Additional interesting find was an upregulation of Angptl4 in hBMC by high glucose treatment (Fig. 3). These results showed the assured association of Angptl4 with high glucose stress.

So far, the precise role of Angptl4 in stem cells with regard to angiogenesis is not well understood, and we have investigated the effect of Angptl4 on angiogenesis activity in hBMCs. Overexpression of Angptl4 in hBMCs almost blocked the tube formation in angiogenesis assay. With these findings, Angptl4 could be suggested as a mediator of high glucose-induced angiogenic dysfunction in BMCs.

The functional consequences of miR-132 in endothelial cells are dependent upon an expression level of p120RasGAP, a negative regulator of Ras. In endothelial cells of tumor tissues, a large amount of miR-132 with minimal amount of p120RasGAP was present. On the other hand, the endothelial cells in normal tissue had abundant p120RasGAP without miR-132. MI-132 has been proposed as an angiogenic switch in the endothelial cells targeting p120RasGAP to activate Ras and result in neovascularization. Recently, miR-132 delivery to human umbilical vein endothelial cells was reported to enhance the microvessels formation. In vascular smooth muscle cells, miR-132 targets LRRFIP1 to repress neointimal hyperplasia in rat carotid artery injury model.

Micro ribonucleic acid-132 is a novel angiogenic modulator in endothelial cells, and we investigated whether miR-132 was involved in high glucose-induced angiogenic dysfunction of hBMCs. The level of miR-132 was higher in high glucose-treated hBMCs than in normal glucose-treated cells. Unexpectedly, however, miR-132 transfected hBMCs showed no tube formation. Additional interesting find was that Angptl4 was increased by miR-132 transfection in hBMCs. In other words, Angptl4 was induced by both high glucose and miR-132 to exert negative effect on tube formation.
mine the sequence of the pathway, miR-132 was quantified in Angpt14-overexpressed hBMCs, and there was no significant change in miR-132 levels. In summary, high glucose induced miR-132 induces Angpt14 via unknown Angpt14 antagonist to exert impaired tube formation in BMCs.

We presumed that the basal level of endogenous miR-132 would be a critical determinant of miR-132 for angiogenesis regulation. In this study, we did not compare the endogenous miR-132 levels of BMCs with other cell such as tumor cells and endothelial cells. To address the role of miR-132 on Angpt14 induction in BMCs, more systematic study is need.

Our data showed that the angiogenic function of BMCs might be disturbed by exposure to the diabetic microenvironment. In this study, we suggested that Angpt14 and miR-132 are involved in the significant aggravation of angiogenic function of high glucose-in-sulted stem cells (Fig. 6). Modulation of Angpt14 or miR-132 could be a promising option for functionally successful autologous cell therapy in diabetic patients.

Acknowledgments

This work was supported by a research grant from the Korean Society of Cardiology in 2011.

References

1. Miyahara Y, Nagaya N, Kataoka M, et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. *Nat Med* 2006;12:459-65.
2. Kim YS, Kwon JS, Hong MH, et al. Restoration of angiogenic capacity of diabetes-insulted mesenchymal stem cells by oxytocin. *BMC Cell Biol* 2013;14:38.
3. Fadini GP, Sartore S, Schiavon M, et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. *Diabetologia* 2006;49:3075-84.
4. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med* 2003;348:593-600.
5. Porrello ER, Olson EN. Building a new heart from old parts: stem cell turnover in the aging heart. *Circ Res* 2010;107:1292-4.
6. Grundy SM, Benjamin JI, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. *Circulation* 1999;100:1134-46.
7. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. *Circulation* 2011;123:e18-209.
8. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. *Diabetes Care* 2006;29:2528-38.
9. Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. *Circulation* 2007;116:2119-26.
10. Rivard A, Silver M, Chen D, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adenov-VEGF. *Am J Pathol* 1999;154:355-63.
11. Loomans CJ, de Koning EI, Staal FJ, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. *Diabetes* 2004;53:195-9.
12. Dernbach E, Randriamboavonjy V, Fleming I, Zeiher AM, Dimmeler S, Urbich C. Impaired interaction of platelets with endothelial progenitor cells in patients with cardiovascular risk factors. *Basic Res Cardiol* 2008;103:572-81.
13. Yang YH, Wang Y, Lam KS, et al. Suppression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4. *Arterioscler Thromb Vasc Biol* 2008;28:835-40.
14. Ito Y, Oike Y, Yasunaga K, et al. Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. *Cancer Res* 2003;63:6651-7.
15. Ma T, Jham BC, Hu J, et al. Viral G protein–coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposis sarcoma. *Proc Nat Acad Sci USA* 2010;107:14363-8.
16. Okochi-Takada E, Hattori N, Tsukamoto T, et al. ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis. *Oncogene* 2013. [Epub ahead of print]
17. Anand S, Majeti BK, Acevedo LM, et al. MicroRNA–132–mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. *Nat Med* 2010;16:909-14.
18. Westenskow PD, Kurihara T, Aguilar E, et al. Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting. *J Clin Invest* 2013;123:4900-8.
19. Devalliere J, Chang WG, Andrejczuk JW, et al. Sustained delivery of proangiogenic microRNA–132 by nanoparticle transfection improves endothelial cell transplantation. *FASEB J* 2014;28:908-22.
20. Choe N, Kwon JS, Kim JR, et al. The microRNA miR–132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia. *Atherosclerosis* 2013;229:348-55.